Phase 3 N=192 Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440
Japanese Encephalitis
Primary: Geometric Mean Titer (GMT) at Day 56 for Anti-JEV Neutralizing Antibodies — 192.2; 202.7 titers — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=130 Transdermal Continuous Oxygen Therapy for Diabetic Foot Ulcers
Diabetic Foot Ulcers
Primary: Number of 100% Wound Closure — 55.74; 50.82 percentage of patients
Phase 3 N=3,057 Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery
Deep Vein Thrombosis · Pulmonary Embolism
Primary: Rate of Adjudicated Venous Thromboembolic Event-related and All-cause Deaths With Onset During the Intended-treatment Period — 15.06; 24.37 Percentage of events/patients…
Phase 3 N=433 Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
Arthritis · Arthritis, Rheumatoid · Autoimmune Diseases
Primary: Percentage of Participants Achieving Erythrocyte Sedimentation Rate (ESR)-Based American College of Rheumatology [ACR] 20 Response at Week 14 — 34.9 percentage of…
Phase 3 N=200 Study of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine in Japanese Subjects
Salmonella Infections · Typhoid Fever · Bacterial Infections
Primary: Number of Participants With At Least a 4-Fold Rise in Vi Antibody Titers Following Vaccination With a Typhoid Vi Polysaccharide Vaccine — 173; 6; 5 Participants
Phase 3 N=116 Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia
Chronic Kidney Disease · Dialysis · Hyperphosphatemia
Primary: Number of Adverse Events (AE) — 109; 50; 63 participants
Phase 3 N=21 Progesterone Treatment for Cocaine-dependent Women: A Pilot Study
Cocaine Dependence
Primary: Cocaine Abstinence Based on Urine Toxicology Results — 1; 3 participants — p=<0.05
Phase 3 N=190 Preservative-Free Tafluprost (MK-2452) for the Treatment of Open-Angle Glaucoma or Ocular Hypertension (MK-2452-002)
Glaucoma · Ocular Hypertension
Primary: Mean Diurnal IOP Change From Baseline at Week 4 - Study Eye — -8.3; -6.6 mmHg
Phase 3 N=602 Periocline as an Adjunct to Scaling and Root Planing for Adult Periodontitis
Adult Periodontitis
Primary: Change in Pocket Depth. — -1.4; -1.6; -1.4 mm
Phase 3 N=1,189 Lot Consistency Study of DTaP-IPV-HB-PRP~T Vaccine Administered at 2-4-6 Months of Age in Healthy Infants
Diphtheria · Tetanus · Pertussis
Primary: Equivalence of Seroprotection Against Vaccine Antigens in Study Participants After Vaccination With Either One of the Batches of DTaP-IPV-HB-PRP~T or Infanrix Hexa™…
Phase 3 N=602 Open-Label Study of Diclofenac Capsules to Treat Osteoarthritis Pain
Osteoarthritis
Primary: Safety of Diclofenac 35 mg Capsules as Assessed by the Incidence of Adverse Events From Baseline to Week 52 or Early Termination — 451; 41; 42 participants
Phase 3 N=119 The Effect of Spironolactone on Blood Pressure in Type-2 Diabetics With Resistant Hypertension
Arterial Hypertension · Hypertension, Resistant to Conventional Therapy · Diabetes Mellitus
Primary: Change of of Systolic Blood Pressure — -9.6; -0.7 mm Hg
Phase 3 N=328 Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection
Chronic Hepatitis C
Primary: Percentage of Participants Achieving Sustained Virologic Response (SVR)12 — 91 percentage of participants — p=< 0.001
Phase 3 N=116 Clinical Study to Evaluate the Efficacy and Safety of Octagam 10% in Idiopathic Thrombocytopenic Purpura in Adults
Immune Thrombocytopenic Purpura
Primary: Percentage of Participants With a Clinical Response — 80.0 Percentage of participants
Phase 3 N=194 Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes
Type 2 Diabetes Mellitus
Primary: Change From Baseline in HbA1c at Week 12 — 0.29; -0.71 percentage of HbA1c